Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by LEO Pharma A/S

LEO Pharma Presents New Late-Breaking Delgocitinib Cream Data For the Third Consecutive Year at AAD 2025
From LEO Pharma A/S
Via Business Wire
LEO Pharma Presents New Long-Term Adbry® (tralokinumab-ldrm) Data in Adults with Moderate-to-Severe Atopic Dermatitis at the 2024 AAD Annual Meeting
From LEO Pharma A/S
Via Business Wire
LEO Pharma Presents Data at 2024 Winter Clinical and Maui Derm Conferences
From LEO Pharma A/S
Via Business Wire
LEO Pharma Presents Adbry® (tralokinumab-ldrm) Data at 2023 Fall Clinical Dermatology Conference
From LEO Pharma A/S
Via Business Wire
LEO Pharma Receives Positive CHMP Opinion for New Adtralza® (tralokinumab) Injection Device
From LEO Pharma A/S
Via Business Wire
Japan Ministry of Health, Labor and Welfare Approves Manufacturing and Marketing of Adtralza® (tralokinumab) in Japan for Adults with Atopic Dermatitis
From LEO Pharma A/S
Via Business Wire
LEO Pharma Announces European Commission Approval of Adtralza® (tralokinumab) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents
From LEO Pharma A/S
Via Business Wire
LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adolescents With Moderate-to-Severe Atopic Dermatitis
From LEO Pharma A/S
Via Business Wire
LEO Pharma to present new data in moderate-to-severe atopic dermatitis and chronic hand eczema at the 31st EADV Congress
From LEO Pharma A/S
Via Business Wire
LEO Pharma Presents New Interim Long-Term Efficacy Data for Adbry™ (tralokinumab-ldrm) in Moderate-to-Severe Atopic Dermatitis at the 2022 RAD Conference
From LEO Pharma A/S
Via Business Wire
LEO Pharma Presents New Interim Long-Term Safety and Efficacy Data for Adbry™ (tralokinumab-ldrm) in Moderate-to-Severe Atopic Dermatitis at the 2022 AAD Annual Meeting
From LEO Pharma A/S
Via Business Wire
LEO Pharma A/S Appoints Brian Hilberdink New President of LEO Pharma Inc. United States
From LEO Pharma A/S
Via Business Wire
Tralokinumab Achieves Primary and Secondary Endpoints in Phase 3 Trial of Adolescents With Moderate-to-Severe Atopic Dermatitis
From LEO Pharma A/S
Via Business Wire
LEO Pharma announces European Commission approval of Adtralza® (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis
From LEO Pharma A/S
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.